Wednesday, November 25, 2015


Market data provided by Barchart; data is delayed per exchange requirements. Terms of Use/Privacy Policy.
Columnists / Reporters
The recent boom in health-care mergers and acquisitions, which resounded loudly with Monday's $160 billion Pfizer/Allergan deal, already involves a small Philadelphia generic-drug company that has spent most of its 73-year existence trying to stay under the radar.
Special Reports
letter icon Newsletter
Print Offers Online